Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1752W HIGH $2.88
Volume
23.59 K
Value Traded
505.35 K
Short % Float
6.97%
-0.22%Week
-22.98%1 Month
-36.54%3 Month
-65.73%6 Month
-99.89%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.09 M
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
4.31 M
Total Shares
39.18 M
Float Shares
39.69 M
Insiders
0.52%
Institutions
2.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AIM Catalyst Timeline
Dated clinical, regulatory and corporate events for AIM ImmunoTech Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AIM ImmunoTech Inc.
587Total events
19Upcoming
111Tier-1 (high impact)
2015 to 2039Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovaldaraxonrasibApprovedFDA Decision
FDA approves daraxonrasib for metastatic pancreatic cancer
metastatic pancreatic cancersource ↗
▲Patent GrantedAmpligenApprovedIP / Competition
US Patent Granted for Ampligen in Combination with Pembrolizumab
cancersource ↗
▲Enrollment CompleteAmpligenApprovedTrial
Enrollment completed ahead of schedule in DURIPANC trial
metastatic pancreatic cancersource ↗
●Last Patient Last VisitAmpligenApprovedTrial
Final patient dosed in DURIPANC trial
metastatic pancreatic cancersource ↗
▲Patent GrantedAmpligenApprovedIP / Competition
European and UK patents granted for Ampligen in Long COVID
Long COVIDsource ↗
●Oral PresentationAmpligenApprovedPresentation
CEO article published in Breaking Defense discussing Ampligen as potential Ebola countermeasure
Ebolasource ↗
▲Enrollment CompleteAmpligenApprovedTrial
Completed patient enrollment and Ampligen dosing in DURIPANC Phase 2 study
metastatic pancreatic cancersource ↗
▲Partnership / LicenseCorporate
Engaged Thermo Fisher Scientific's PPD for Phase 3 study design support
▲Last Patient Last VisitAmpligenApprovedTrial
Final subject received last dose of Ampligen in DURIPANC trial
metastatic pancreatic cancersource ↗
▲Enrollment CompleteAmpligenApprovedTrial
Successful completion of patient enrollment and dosing in DURIPANC study
pancreatic cancersource ↗
▲Interim AnalysisAmpligenApprovedTrial
Encouraging interim clinical observations
pancreatic cancersource ↗
▲Safety Data UpdateAmpligenApprovedClinical Data
Continued favorable safety findings
pancreatic cancersource ↗
▲Partnership / LicenseAmpligenApprovedCorporate
Strategic collaboration with AstraZeneca and Erasmus Medical Center
pancreatic cancersource ↗
◆Oral PresentationPresentation
AIM ImmunoTech to present in Webull Corporate Connect Webinar Series
▲Enrollment CompleteAmpligenApprovedTrial
Completed Phase 2 DURIPANC enrollment ahead of schedule
metastatic pancreatic cancersource ↗
▲Last Patient Last VisitAmpligenApprovedTrial
Dosed the final patient in the DURIPANC study
metastatic pancreatic cancersource ↗
▲Interim AnalysisAmpligenApprovedTrial
Reported positive interim clinical updates from DURIPANC
metastatic pancreatic cancersource ↗
▲Patent GrantedAmpligenApprovedIP / Competition
Expanded and strengthened global IP protection surrounding Ampligen and checkpoint inhibitor combinations
▲Orphan Drug DesignationAmpligenApprovedDesignation
Maintained orphan drug designation for pancreatic cancer in major markets
pancreatic cancersource ↗
▲First Patient DosedAmpligenApprovedTrial
Final subject received first dose in Phase 2 DURIPANC study
metastatic pancreatic cancersource ↗
▲Quarterly UpdateCorporate
Regained compliance with NYSE American continued listing standards
◆Restructuring LayoffsCorporate
Deadline to regain compliance with NYSE American continued listing standards
▼Equity OfferingCorporate
Issuance of 2,554,119 shares, pre-funded warrants, and Class J warrants for $2.6M
▼Equity OfferingCorporate
Announced $2.65 million financing priced at-market under NYSE American rules
▲Enrollment CompleteAmpligenApprovedTrial
Enrollment of final patient in DURIPANC study
metastatic pancreatic cancersource ↗
◆Oral PresentationAmpligenApprovedPresentation
Virtual Investor 'Ebola: What This Means' Segment Release
Ebola virus diseasesource ↗
▲Enrollment CompleteAmpligenApprovedTrial
Enrollment completed ahead of schedule in DURIPANC Phase 2 trial
metastatic pancreatic cancersource ↗
◆Interim AnalysisAmpligenApprovedTrial
Next interim report to be published in next two to three weeks
metastatic pancreatic cancersource ↗
◆Timing GuidanceAmpligenApprovedPresentation
Next DURIPANC update expected in June 2026
metastatic pancreatic cancersource ↗
▼Equity OfferingCorporate
Announced $2.4 million registered direct offering and concurrent private placement of Series I warrants
▲Primary Endpoint MetAmpligenApprovedClinical Data
Final Primary Endpoint Report: 50% ORR in recurrent ovarian cancer Phase 2 trial
recurrent ovarian cancersource ↗
◆Oral PresentationPresentation
CEO Thomas K. Equels to participate in Virtual Investor Closing Bell Event
▼Going ConcernCorporate
Audit report with going concern emphasis of matter for fiscal year 2025
◆Enrollment CompleteAmpligenApprovedTrial
Expected completion of enrollment in TNBC trial
metastatic or unresectable triple negative breast cancersource ↗
▲Quarterly UpdateCorporate
Reported stockholder equity of approximately $2.1 million as of March 31, 2026
▲Patent GrantedAmpligenApprovedIP / Competition
Japan patent covering Ampligen with checkpoint inhibitors fully approved
cancersource ↗
▼Equity OfferingCorporate
Rights offering expired with preliminary gross proceeds of $1.8 million
▲Partnership / LicenseAmpligenApprovedCorporate
Agreement with PPD to design Phase 3 trial of Ampligen in late-stage pancreatic cancer
late-stage pancreatic cancersource ↗
◆Other Regulator MilestoneAmpligenApprovedEx-US Regulatory
Company announced in March 2026 it would seek orphan drug status in Japan
pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How AIM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-10-18 | Ampligen | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$8M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.2x
rNPV / MCap
Top 35%
Micro Cap(rank 231 of 658)
Percentile Rank
AIM ImmunoTech Inc. carries a moderate pipeline score (41/100), with $1.3B risk-adjusted pipeline value, led by poly I-poly C12U in HIV Seropositivity (Phase 2), across $57B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| poly I-poly C12U Small moleculeCompletedNCT00035893 | HIV Seropositivity | Phase 2 | COMPLETED | 40 | Aug 1, 2006 |
Clinical Trial Results
Readouts, endpoints and source filings for every AIM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Ampligen Orphan | pancreatic cancer | 2026-09-22 | 34.8 monthsRead More | AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ DaraxonrasibRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Equels Thomas KDirector, Officer (CEO & President) | Buy | 24,000 126,822 held | $0.21 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AIM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AIM for Q2 2026. | ||||
AIM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AIM ranks across every disease it competes in
Competitive Position is a premium feature
See how AIM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAIM News
AIM▲ +0.8%today
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech's strategy to address immune resistance in pancreatic cancer was highlighted in a BioTuesdays feature. The article discusses the potential of Ampligen as a maintenance therapy following chemotherapy and its role in converting 'cold' tumors to a more immunologically active state. AIM is awaiting results from the DURIPANC trial and aims to translate findings into pivotal development.
Read more →AIM▲ +5.6%on this newsshared move
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
AIM ImmunoTech has garnered media attention for Ampligen's potential as a broad-spectrum antiviral and its applications in biodefense. The drug may help combat emerging viral threats and is being explored for its efficacy against solid tumors. The company is also expanding its intellectual property portfolio related to Long COVID. However, clinical trials are necessary to validate these claims.
Read more →AIM▲ +7.3%on this newsshared move
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
AIM ImmunoTech has garnered media attention for its Ampligen® strategy in metastatic pancreatic cancer, particularly as the Phase 2 DURIPANC trial progresses. The trial aims to address immune resistance and has shown promising results in previous studies. The company expects topline results in early 2027, which could inform future clinical trials.
Read more →AIMAIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
AIM ImmunoTech's CEO discusses Ampligen's potential role in pancreatic cancer treatment in a new video. The company highlights encouraging survival data from a Dutch program where patients received Ampligen after chemotherapy. AIM is advancing its Phase 2 DURIPANC study, aiming to evaluate Ampligen's efficacy alongside AstraZeneca's durvalumab, with results expected in early 2027.
Read more →AIMAIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
AIM ImmunoTech's CEO highlighted Ampligen's potential in pancreatic cancer treatment following the FDA approval of daraxonrasib. Ampligen demonstrated a median overall survival of 34.8 months in a specific patient group, significantly better than historical controls. The company believes Ampligen can complement existing therapies and is conducting the DURIPANC trial to explore its efficacy further.
Read more →AIMAIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
AIM ImmunoTech has released a new CEO Corner video highlighting the ongoing Phase 2 DURIPANC study of Ampligen in pancreatic cancer. The study aims to evaluate Ampligen's ability to reshape the tumor microenvironment and enhance the effectiveness of checkpoint inhibitors. CEO Thomas K. Equels emphasized the challenges of pancreatic cancer and the potential of Ampligen to address these issues. The company continues to build scientific evidence and engage in regulatory discussions to refine its development strategy.
Read more →AIMAIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech has announced the expansion of its patent protections for Ampligen in Europe and the UK, specifically for treating Long COVID, extending through June 2041. This follows a recent U.S. patent for Ampligen in cancer treatment. The company aims to build a robust global patent estate around Ampligen, enhancing its market position.
Read more →AIM▼ -12.5%on this newsshared move
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
AIM ImmunoTech has received a U.S. patent for the use of Ampligen in combination with pembrolizumab for cancer treatment. This patent, expiring in 2039, covers various cancers, including pancreatic cancer. The CEO highlighted the patent's role in strengthening the company's intellectual property portfolio and its long-term oncology strategy. Ampligen is positioned as a promising candidate in cancer immunotherapy.
Read more →AIMAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
AIM ImmunoTech participated in the Virtual Investor 'Why Now' conference, where CEO Thomas Equels presented the company's investment thesis. He highlighted the progress of Ampligen in the Phase 2 DURIPANC clinical trial for metastatic pancreatic cancer, noting that enrollment was completed ahead of schedule and that topline results are expected in early 2027.
Read more →AIMAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
AIM ImmunoTech's CEO, Thomas K. Equels, published an article in 'Breaking Defense' advocating for proactive biodefense measures, emphasizing the potential of Ampligen as a broad-spectrum antiviral against Ebola. He argues that military readiness should incorporate medical countermeasures before biological threats emerge. The article discusses preclinical studies supporting Ampligen's efficacy and calls for government support for further research.
Read more →AIM▼ -7.8%on this newsshared move
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
AIM ImmunoTech reported its second quarter 2026 financial results, highlighting the completion of enrollment in its Phase 2 trial for Ampligen in metastatic pancreatic cancer. The company is preparing for a pivotal Phase 3 trial, with key data expected in early and late 2027. AIM also aims to explore government funding for Ebola initiatives while maintaining focus on pancreatic cancer.
Read more →AIMAIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
AIM ImmunoTech has announced that the last subject in the Phase 2 DURIPANC clinical trial has received their final dose of Ampligen ahead of schedule. The trial evaluates Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. Primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in Q1 2027. Previous exploratory results indicated promising overall survival rates, particularly in patients with specific immune biomarkers.
Read more →AIMAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech announced the release of a CEO Corner segment highlighting the company's advancements in its pancreatic cancer program. CEO Thomas Equels discussed the successful completion of patient enrollment in the DURIPANC Phase 2 clinical trial of Ampligen in combination with AstraZeneca's Imfinzi. The company is optimistic about its future, citing significant clinical and operational milestones.
Read more →AIMAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
AIM ImmunoTech has made significant strides in its pancreatic cancer program, particularly with Ampligen, which is currently in the Phase 2 DURIPANC study. The company has achieved key milestones, including completing enrollment and dosing the final patient. Management anticipates a pivotal period ahead, with multiple clinical updates and potential advancements toward Phase 3 planning.
Read more →AIMAIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
AIM ImmunoTech Inc. announced its participation in the Webull Corporate Connect Webinar Series scheduled for June 24-25, 2026. CEO Thomas Equels will present during the event, discussing the company's advancements and its lead product, Ampligen, which is aimed at treating late-stage pancreatic cancer. The webinar offers a platform for AIM to engage with investors and stakeholders.
Read more →AIM▼ -5%on this newsshared move
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech has reached a significant milestone in its Phase 2 DURIPANC study for metastatic pancreatic cancer, with the final subject receiving their first dose. The study evaluates Ampligen in combination with AstraZeneca's Imfinzi, aiming to assess clinical benefit rates and overall survival. Primary endpoint analysis is expected in December 2026, with topline results anticipated in Q1 2027.
Read more →AIMAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
AIM ImmunoTech Inc. has announced its compliance with NYSE American's listing standards after resolving stockholder equity deficiencies. The company raised approximately $8.5 million through warrant exercises and stock sales, ensuring its equity exceeds the minimum requirement. The NYSE American confirmed the removal of the 'below compliance' indicator from AIM's trading symbol.
Read more →AIM▼ -22.3%on this news
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
AIM ImmunoTech Inc. has announced a registered direct offering and private placement, aiming to raise approximately $2.65 million. The financing will support clinical drug supply, current and planned Phase 3 clinical trial activities, and working capital. The offering is expected to close around June 10, 2026, pending customary conditions.
Read more →AIMAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech has reported positive interim results from its Phase 2 study evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. The final patient has been enrolled, and the company anticipates a December 2026 evaluation of the primary endpoint. Previous studies suggest Ampligen may significantly improve survival rates compared to standard treatments.
Read more →About AIM ImmunoTech Inc.
Headquarters2117 SW HIGHWAY 484, OCALA, FL, 32801
Founded12-07-1996
BIOPHARMAWATCH ELITE PLUS
Trade the next AIM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime